Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q3 2021 Earnings Presentation
13 slides from Harmony Biosciences's earnings presentation, Nov 9, 2021
Slide 1: Harmony Biosciences Q3 2021 Financial and Business Update
Harmony Biosciences Q3 2021 Financial and Business Update November 9, 2021 Exhibit 99.2
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, I
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Optimize WAKIX ® Performance Expand Clinical Utility of WAKIX Acquire New Assets 3
Slide 4: Q3 2021 WAKIX Revenue Performance
4 Q3 2021 WAKIX Revenue Performance Continued Growth with Q3 Revenue of $80.7M 3Q20 2Q21 3Q21 3Q21 vs. 2Q21 3Q21 vs. 3Q20 $45.6 $73.8 $80.7 9.4% 77% Strong Revenue Growth in Q3 2021 ▪ 9.4% growth Q3 2021 vs. Q2 2021 ▪ 77% growth Q3 2021 vs. Q3 2020 ▪ Continued sequential quarter over quarter growth
Slide 5: Driving Growth Through Our Launch For WAKIX
Driving Growth Through Our Launch For WAKIX Q3 2021 Performance 5 Average # of WAKIX Patients Of 8,000 unique HCPs have prescribed WAKIX since launch U.S. Covered Lives With Formulary Access ~3,500 ~80% ~40% Healthcare Professional Educational Initiatives Managed Care Education & Outreach Patient Ou
Slide 6: Majority of HCPs Expect to Increase Future Use of WAKIX
6 The Majority of HCPs (MDs & NP/PAs) Stated They Expect to Increase Future Use of WAKIX® in Both Type 1 & Type 2 Patients MDs n=187 NP/PAs n=25 Q: For WAKIX, do you expect your prescribing to increase, decrease or stay the same? Source: Harmony Market Research (total n=212); Q: MD-Type 1=172 respon
Slide 7: AASM Treatment Guideline on Central Disorders of Hypersomnolence
AASM Treatment Guideline on Central Disorders of Hypersomnolence 7 Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline Kiran Maski, MD, MPH; Lynn Marie Trotti MD, MSc; Suresh Kotagal, MD; Robert R Auger MD; James A Rowley MD; Sarah D H
Slide 8: New Data for WAKIX Presented at SLEEP 2021
8 Assessment of the Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy. Meskill GM et al. Poster presentation at SLEEP, June 10 – 13, 2021. New Data for WAKIX Presented at SLEEP 2021
Slide 9: New Data for WAKIX Presented at SLEEP 2021
9 New Data for WAKIX Presented at SLEEP 2021 Assessment of the Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy. Meskill GM et al. Poster presentation at SLEEP, June 10 – 13, 2021.
Slide 10: Harmony Pipeline
Harmony Pipeline [S e HARMONY ESS Se Lae EE WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) Pitolisant Narcolepsy (Pediatrics)? Prader-Willi Top line Syndrome (PWS) data 1H2022 Myotonic Top line Dystrophy (DM) data 2H2022 HBS-102 Other Neurological Diseases 1. Includes New Drug Ap
Slide 11: Historical Financials
|e -_s mi | Historical Financials H3 ie ponaedere
Slide 12: Q3 2021 Financial Summary
Q3 2021 Financial Summary (in millions, USD) 12 Three Months Ended September 30, 2021 2020 Net Product Revenues $ 80.7 $ 45.6 Cost of Product Sold 14.6 7.9 Total Operating Expenses $ 45.1 $ 27.3 R&D Expense 11.7 4.2 S&M Expense 16.5 12.6 G&A Expense 16.9 10.5 Net (Loss) Income $ (9.6) $ 1.9 Cash & c
Slide 13: GAAP vs Non-GAAP Reconciliation
GAAP vs Non-GAAP Reconciliation (in millions, USD) 13 Three Months Ended September, 2021 2020 GAAP reported net (loss) income $ (9.6) $ 1.9 Interest expense / income 5.4 6.9 Taxes (0.9) Depreciation 0.1 0.1 Amortization 4.6 1.9 EBITDA (0.4) 10.8 Stock-based compensation expense 4.7 1.3 Loss on debt
Harmony Biosciences Holdings — Q3 2021 Earnings Presentation on 6ix